-
ASCO 2025 Recap: Rise of the Bispecifics, Dueling Degraders, ADCs of Interest & More
16 Jun 2025 02:20 GMT
… first-line treatment with an aromatase inhibitor alongside a CDK4/6 … allowed to switch out the aromatase inhibitor for the AstraZeneca drug. Results …
-
ASCO 2025: Cost-Effectiveness of Ribociclib in Early Breast Cancer
15 Jun 2025 16:11 GMT
… ) plus endocrine therapy, a nonsteroidal aromatase inhibitor (NSAI), significantly improved invasive disease …
-
VIDEO: Camizestrant combination reduces risk for breast cancer progression, mortality
15 Jun 2025 15:12 GMT
… continued standard treatment with an aromatase inhibitor plus a CDK 4…
-
Lead Investigator Insights on Adjuvant Endocrine Therapy Landscape
13 Jun 2025 21:21 GMT
… . Common agents include tamoxifen and aromatase inhibitors, with ovarian function suppression sometimes … , agents such as tamoxifen and aromatase inhibitors are used preventively, such as …
-
Supporting pet owning clients with cancer, and survivors
13 Jun 2025 22:28 GMT
… (e.g., tamoxifen/Nolvadex, aromatase inhibitors) (229/930, 24.6% …
-
ASCO 2025: Ribociclib With NSAI in HR+/HER– Breast Cancer Improves iDFS, Yields Substantial Work Productivity Gains
13 Jun 2025 19:42 GMT
… ) in combination with a nonsteroidal aromatase inhibitor (NSAI) in the adjuvant treatment … Ribociclib in Combination With an Aromatase Inhibitor for HR+/HER2- Early … -ribociclib-in-combination-with-an-aromatase-inhibitor-for-hr-her2--early-breast …
-
Screening Perfumes for Hazardous Substances Using Thin-Layer Chromatography
13 Jun 2025 21:12 GMT
… perfume and the half-maximal aromatase inhibitory dose (IC50) was 11 nL …
-
Navigating Vasomotor Symptoms From Endocrine Therapy in Breast Cancer Treatment
13 Jun 2025 21:21 GMT
… intense and frequent hot flashes. Aromatase inhibitors also cause vasomotor symptoms but …
-
Benign Breast Disease: More Common Than You Think
13 Jun 2025 18:45 GMT
… , such as tamoxifen or an aromatase inhibitor, may be recommended to help …
-
Serial ESR1 Mutation Testing in HR+/HER2– mBC: Insights From SERENA-6
13 Jun 2025 14:10 GMT
… outcomes. Patients who switched from aromatase inhibitors to elacestrant upon ESR1 mutation …